Three-dimensional cancer organoid cultures have significantly advanced the investigation of therapy resistance. By faithfully preserving the genomic and transcriptomic profiles of the original individual tumors, these models demonstrate a high degree of predictive accuracy in drug response assays. Derived either directly from patient specimens or through controlled induction with anti-cancer agents, drug-resistant tumor organoids establish a critical translational platform between conventional two-dimensional cultures and complex in vivo systems. They thereby provide a physiologically relevant model for elucidating the intricate mechanisms underlying therapy failure, tumor progression, and adaptive interactions within the tumor microenvironment.
Resistant tumor organoid platforms are strategically employed to bridge critical stages of drug development, spanning from lead optimization to subsequent preclinical evaluation. This high-fidelity system supports diverse investigational needs, including the evaluation of novel small molecules, antibody-drug conjugates (ADCs), and the discovery of synergistic drug combinations, thereby accelerating the discovery of therapies that can overcome resistance and resensitize tumors.
| Cancer Type | Therapy-resistance Type | Description |
| Gastric cancer | 5-FU | Gastric cancer organoids are established directly from surgical patient specimens. 5-FU-resistant models are developed through continuous, stepwise escalation of 5-FU concentration in the culture medium. |
| Oxaliplatin(L-OHP) | L-OHP-resistant organoid lines are established by supplementing the culture medium with incrementally increasing doses of L-OHP over time. | |
| Pancreatic adenocarcinoma (PDAC) | Gemcitabine | Gemcitabine-resistant organoids are derived directly from PDAC individuals with confirmed gemcitabine resistance. |
| Prostate cancer | Androgen pathway directed therapy (APDT) | APDT-resistant organoids are established following a 4-week APDT therapy regimen, maintained in either androgen-depleted conditions or with the anti-androgen enzalutamide. |
| Ovarian cancer | Cisplatin | Cisplatin-resistant PDOs are generated from ovarian cancer tissues of cisplatin-resistant patients and subsequently maintained under cisplatin therapy for 21 days to validate the resistant phenotype. |
Leveraging a proprietary and optimized organoid culture platform, deep expertise in oncology, and a robust translational research workflow, Alfa Cytology delivers reproducible drug-resistant tumor organoid models. Our end-to-end service encompasses expert consultation, model development, thorough molecular and functional characterization, and dedicated project support to ensure these powerful tools seamlessly integrate into your research pipeline for preclinical validation and mechanistic studies.
Our service portfolio includes the development of drug-resistant organoid models across a wide spectrum of solid tumors, with established protocols for cancers such as colorectal and gastric, among others. We tailor the culture conditions and validation assays to the specific biological requirements of each cancer type and its associated resistance phenotype.
Resistant Cancer Patient-derived Organoid Model Development
This approach involves the direct derivation and culture of organoids from tumor tissue biopsies or malignant effusions obtained from patients who have relapsed or demonstrated disease progression following a specific therapy. These models inherently capture the complex, evolved resistance mechanisms present in the patient, including genetic mutations, tumor microenvironment interactions, and adaptive cellular states.
Drug-Induced Resistant Organoid Model Development
Beyond utilizing naturally resistant samples, we employ chronic, dose-escalation exposure strategies to generate de novo resistant lines from sensitive parental organoids. This involves the long-term, incremental exposure of tumor organoids to a therapeutic agent in vitro, followed by selection and expansion of the resistant population. This method allows for the study of acquired resistance dynamics and early identification of potential resistance pathways.
Alfa Cytology's comprehensive suite of research services is designed to fully leverage the potential of your drug-resistant organoid models. We provide end-to-end solutions to decrypt resistance mechanisms, validate novel therapeutic strategies, and generate reliable data, accelerating your translational oncology research.
Multi-Omic Characterization and Validation
We confirm the resistant phenotype using an integrated multi-omic method. By applying WES and RNA-Seq, we map the genomic and transcriptomic alterations driving drug escape. Direct comparison between resistant and parental sensitive lines identifies key resistance mechanisms, such as pathway activation, EMT, or efflux pump upregulation, ensuring molecular fidelity.
Tumor Microenvironment (TME) Integration
Recognizing that resistance is often mediated by extrinsic factors, our service includes the co-culture of tumor organoids with essential TME components, such as CAFs and immune cells. This recapitulates the protective niche and enables the study of microenvironment-mediated resistance, including evaluation of immunotherapies in a relevant context.
High-Throughput Pharmacological Profiling
Using automated, high-throughput screening platforms and validated viability assays, we precisely quantify resistance. The service determines IC50 shifts and calculates resistance indices (RI) from dose-response curves, delivering a quantitative benchmark for evaluating novel or combination therapies aimed at overcoming resistance.
To investigate the underlying mechanisms of oxaliplatin (L-OHP) resistance in gastric cancer, a project was initiated to develop and characterize stable L-OHP-resistant gastric cancer organoids (GCOs). Resistant lines were established from GCOs through a sustained, incremental dose-escalation protocol in culture, successfully generating resistant models. Viability assays confirmed that the organoid exhibited an approximately 3.5-fold increase in IC50 values compared to its parental lines, demonstrating robust and stable resistance. Phenotypic characterization revealed morphological shifts in the resistant organoids, including increased budding structures and distinct nuclear features upon histological analysis, which are associated with a cancer stem cell (CSC)-like state. These results suggested that our systematic approach to generating physiologically relevant and validated resistant-organoid models offers insights into mechanisms and translational relevance in oncology research.
Fig.1 The dose-response relationships of parental and L-OHP-resistant GCOs to L-OHP were determined by MTT assay. Data are presented as mean ± SEM (n=5; **p < 0.01).
Contact Us
Empowering oncology research and therapeutic discovery, Alfa Cytology's integrated suite of drug-resistant tumor organoid development and analysis services offers a reliable in vitro platform to decode and combat therapy failure. To discuss your specific project requirements and how our models can advance your research goals, please contact our scientific team for a detailed consultation.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.